Monte Rosa Therapeutics (GLUE) Equity Ratio (2020 - 2026)

Monte Rosa Therapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.71 for Q1 2026.

• In Q1 2026, Equity Ratio rose 1.27% year-over-year to 0.71; the TTM figure through Mar 2026 stood at 0.71 (up 1.27% YoY), while the FY2025 annual figure was 0.52, up 2.23% from the prior year.
• Equity Ratio was 0.71 for Q1 2026 at Monte Rosa Therapeutics, up from 0.52 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.94 in Q1 2022 to a low of 0.51 in Q4 2024.
• Historically, Equity Ratio has averaged 0.7 across 5 years, with a median of 0.71 in 2026.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio dropped 27.5% in 2024, then gained 22.39% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.79 in 2022, then declined by 25.56% to 0.59 in 2023, then declined by 13.89% to 0.51 in 2024, then grew by 2.23% to 0.52 in 2025, then jumped by 36.44% to 0.71 in 2026.
• The last three Equity Ratio figures came in at 0.71 (Q1 2026), 0.52 (Q4 2025), and 0.53 (Q3 2025), per Business Quant data.